Claudin 18.2 in Gastric Cancer
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Released: March 28, 2023

Gregory Botta
Gregory Botta, MD, PhD
Samuel Klempner
Samuel Klempner, MD

Activity

Progress
1
Course Completed

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:

  • Expression patterns and function of the claudin family of proteins in normal gastric tissues
  • Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology
  • Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers
  • Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection
  • Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs